[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-444872-105":59,"doc-detail-444872-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","plain-language-summary-of-publication-preferences-for-pulmonary-arterial-hypertension-pah-medications","Plain Language Summary of Publication - Preferences for pulmonary arterial hypertension (PAH) medications","","Plain Language Summary of Publication focusing on patient and doctor preferences for pulmonary arterial hypertension (PAH) medications, based on interviews from the A DUE phase 3 clinical study. The study explored a single-tablet (single-pill) combination therapy containing macitentan and tadalafil versus earlier 4-pill daily dosing with placebo-controlled blinding. Results show patients and clinicians viewed 1 pill per day as easier, reducing stress and pill burden, and supporting adherence. Findings inform shared decision-making in PAH treatment choices.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/plain-language-summary-of-publication-preferences-for-pulmonary-arterial-hypertension-pah-medications/444872/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/plain-language-summary-of-publication-preferences-for-pulmonary-arterial-hypertension-pah-medications/444872.png","ImageObject",300,407,{"name":92,"@type":93},"Blue Pony","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the A DUE phase 3 study summarized in this plain language summary?","Question",{"text":112,"@type":113},"The A DUE study is a phase 3 clinical study that investigated a single-tablet (single-pill) combination therapy for people living with PAH. It included qualitative interviews with patients and doctors after the treatment period.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the dosing work during the clinical study?",{"text":117,"@type":113},"Participants were split into groups receiving macitentan only, tadalafil only, or the single-pill combination therapy, for 16 weeks. All groups received 4 pills a day during this phase to keep medication assignment blinded, then everyone received the single-pill combination for up to 2 years.",{"name":119,"@type":110,"acceptedAnswer":120},"What did patients and doctors consider the most important benefit of one pill per day?",{"text":121,"@type":113},"Both patients and doctors reported that taking 1 pill per day was easier than taking multiple pills per day and reduced stress and worries about managing treatment. They also felt that fewer pills could help patients take medication as recommended (adherence).",{"name":123,"@type":110,"acceptedAnswer":124},"How do the findings support treatment decision-making for PAH?",{"text":125,"@type":113},"The summary states the results are relevant for shared decision-making, where patients and doctors work together to make choices reflecting the patient’s values, priorities, and preferences. The interview findings support the use of the single-pill combination therapy for PAH.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},444872,1790778833,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":41,"preview_page_count":4},962090760266,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Plain Language Summary of Publication  \nPreferences for pulmonary arterial hypertension (PAH) medications: plain language summary on insights from interviews with patients and doctors in the A DUE phase 3 clinical study  \nFenling Fana, Stacy Davisb, Claire Burbridgec, Kelly Chind, Michael Friberge, Ekkehard Grünigf, Melanie Hughesc , Pavel Jansag, Gerry Langanh, Jörg Linderi, Jennifer Rafalskij, Alvaro Agustin Rodriguezk & Jason A. Randallc  \nAuthor affiliations can be found at the end of this article.  \nFirst draft submitted: 19 May 2025; Accepted for publication: 25 September 2025  \nWhere can I find the original article on which this summary is based?  \nThis summary is based on the article titled ‘Single-tablet combination therapy of macitentan/tadalafil for patients with pulmonary arterial hypertension: qualitative interview study of the A DUE phase 3 trial’, which is free to access and can be read at: [https://rdcu.be/eelKa](https://rdcu.be/eelKa).  \nSummary  \nWhat is this summary about?  \nThis article presents insights from interviews with 26 patients and 18 doctors who took part in a phase 3 clinical study, called theA DUE study. This study investigated a single-tablet (or single-pill) combination therapy in people living with pulmonary arterial hypertension (PAH), a severe and rare progressive lung condition. The single-pill combination therapy contains 2 medications to treat PAH (macitentan and tadalafil) and is now approved in several countries.  \nHow to say (download PDF and double click sound icon to play sound)...  \n• Pulmonary: PUHL-muh-nuh-ree  \n• Arterial: aa-TEEUH-ree-uhl  \n• Hypertension: hai-puh-TEN-shn  \n• Macitentan: MA-si-TEN-tan  \n• Tadalafil: ta-DAL-a-fil  \nIn the clinical study, patients were split into 3 different groups (macitentan only, tadalafil only, or single-pill combination therapy only) for 16 weeks. Patients in all groups were given 4 pills a day to treat PAH. Some of these were placebo pills. This was to ensure nobody knew which medication they were taking until the end of the study, to avoid biased results. After 16 weeks, all patients received only the single-pill combination therapy (1 pill per day) for up to 2 years. The interviews occurred during or within 2 weeks after this 2-year period finished.  \nWhat was this interview study about?  \nPatients and doctors from the clinical study were asked about their thoughts on PAH treatment, their experience with the single-pill combination therapy compared with the 4 pills required earlier in the study, and how it might impact patients taking medication as recommended (known as adherence) .  \nWhat were the key takeaways?  \nThe interviews with patients and doctors revealed that taking 1 pill a day for PAH was considered easier than taking multiple pills per day (4 in this study) and reduced stress and worries around managing multiple pills. Both patients and doctors felt that 1 pill would reduce the pill burden and help patients take their medication as recommended. The findings are relevant for shared decision-making on treatment options for PAH. Shared decision-making describes the process where patients and doctors work together to make decisions that reflect what matters most to the patient - their  \nvalues, priorities and preferences. In summary, these results provide support from both patients and doctors for the use of the single-pill combination therapy in the medication of PAH.  \n10. 1080/14796678 .2025. 2567782 © 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ([http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/)), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manusc","cbCaisM5e2tvlJ8s","https://ap.wps.com/l/cbCaisM5e2tvlJ8s","pdf",2277053,12,"English","# Summary\n## What is this summary about?\n## How was the study designed?\n## What was this interview study about?\n## What were the key takeaways?\n## What is the purpose of this plain language summary?\n## Who is this article for?\n## Who sponsored this study?\n## Glossary","[{\"question\":\"What is the A DUE phase 3 study summarized in this plain language summary?\",\"answer\":\"The A DUE study is a phase 3 clinical study that investigated a single-tablet (single-pill) combination therapy for people living with PAH. It included qualitative interviews with patients and doctors after the treatment period.\"},{\"question\":\"How did the dosing work during the clinical study?\",\"answer\":\"Participants were split into groups receiving macitentan only, tadalafil only, or the single-pill combination therapy, for 16 weeks. All groups received 4 pills a day during this phase to keep medication assignment blinded, then everyone received the single-pill combination for up to 2 years.\"},{\"question\":\"What did patients and doctors consider the most important benefit of one pill per day?\",\"answer\":\"Both patients and doctors reported that taking 1 pill per day was easier than taking multiple pills per day and reduced stress and worries about managing treatment. They also felt that fewer pills could help patients take medication as recommended (adherence).\"},{\"question\":\"How do the findings support treatment decision-making for PAH?\",\"answer\":\"The summary states the results are relevant for shared decision-making, where patients and doctors work together to make choices reflecting the patient’s values, priorities, and preferences. The interview findings support the use of the single-pill combination therapy for PAH.\"}]","Plain Language Summary of Publication - Preferences for pulmonary arterial hypertension (PAH) medications | PDF",1790709573]